Other Information.
+Added: Insider Trading Arrangements
+Added: On June 13, 2025 , Dr.
+Added: Efthymios Deliargyris , our Chief Medical Officer , adopted a Rule 10b5-1 trading plan for the sale of the Company’s common stock.
+Added: The plan, which has a term of one year, provides for the sale of up to 157,500 incentive stock options through market or limit orders.
+Added: Other than the individual disclosed above, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.
Certification of Principal Executive Officer pursuant to 18 U.S.C.
6 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of Sarbanes Oxley Act of 2002.*
−Removed: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024, (ii) Consolidated Statements of Operations for the three months ended March 31, 2025 and 2024, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three months ended March 31, 2025 and 2024, (iv) Consolidated Statements of Cash Flows for the three months ended March 31, 2025 and 2024 and (v) Notes to Condensed Consolidated Financial Statements.
+Added: The following materials from CytoSorbents Corporation’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024, (ii) Consolidated Statements of Operations for the three and six months ended June 30, 2025 and 2024, (iii) Consolidated Statement of Changes in Stockholders’ Equity for the three and six months ended June 30, 2025 and 2024, (iv) Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 and (v) Notes to Condensed Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
2 unchanged sentences
CYTOSORBENTS CORPORATION
+Added: August 7, 2025
/s/ Phillip P.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 7, 2025
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.